<DOC>
	<DOCNO>NCT01389323</DOCNO>
	<brief_summary>The purpose study compare rate sustain virologic response cohort ( Black-African Americans , Latinos ) study historical rate .</brief_summary>
	<brief_title>BMS-790052 ( Daclatasvir ) Plus Peg-Interferon Alfa-2a Ribavirin Treatment-Naive Black/African-Americans , Latinos White/Caucasians With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants chronically infect Hepatitis C virus ( HCV ) genotype 1 HCV RNA viral load ≥10,000 IU/mL screen No previous exposure interferon formulation , ribavirin HCV direct antiviral agent Selfdescribed BlackAfrican American , Latino WhiteCaucasian Results liver biopsy obtain ≤36 month prior first treatment compensate cirrhotics HCV liver biopsy time prior first treatment . Compensated cirrhotics cap approximately 25 % Evidence decompensated liver disease Documented suspect Hepatocellular carcinoma ( HCC ) Positive Hepatitis B HIV 1/HIV 2 antibody screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>